Previous close | 26.03 |
Open | 26.03 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 116.00 |
Expiry date | 2024-06-28 |
Day's range | 26.03 - 26.03 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Walgreens is closing several stores and pulling back on VillageMD locations as it restructures the company.
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $144.49, denoting a +0.57% change from the preceding trading day.
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. Related: FDA Appr